Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission?

Research output: Contribution to journalReview article

Abstract

Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.

Original languageEnglish (US)
Pages (from-to)495-501
Number of pages7
JournalAnnals of Dermatology
Volume31
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Psoriasis
Tumor Necrosis Factor-alpha
Costs and Cost Analysis
Biological Products
Disease Progression
Therapeutics
Clinical Trials
Guidelines

Keywords

  • Discontinuation
  • Psoriasis
  • Remission
  • Tumor necrosis factor antagonist
  • Withdrawal

ASJC Scopus subject areas

  • Dermatology

Cite this

Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission? / Kim, Byungsoo; Maverakis, Emanual; Raychaudhuri, Siba P.

In: Annals of Dermatology, Vol. 31, No. 5, 01.01.2019, p. 495-501.

Research output: Contribution to journalReview article

@article{67c0d7f2157f420aaad7eacafa595999,
title = "Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission?",
abstract = "Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.",
keywords = "Discontinuation, Psoriasis, Remission, Tumor necrosis factor antagonist, Withdrawal",
author = "Byungsoo Kim and Emanual Maverakis and Raychaudhuri, {Siba P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.5021/ad.2019.31.5.495",
language = "English (US)",
volume = "31",
pages = "495--501",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "5",

}

TY - JOUR

T1 - Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission?

AU - Kim, Byungsoo

AU - Maverakis, Emanual

AU - Raychaudhuri, Siba P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.

AB - Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threatening adverse events. Recently, there has been an increasing interest in discontinuing TNF antagonists in patients with psoriasis who have achieved a positive clinical response. However, there is a paucity of data and clinical guidelines concerning the cessation TNF antagonists in psoriasis treatment. Several factors, including cost, subsequent treatment efficacy, relative risks, and tolerability, should be considered before the decision is made to discontinue TNF antagonists. Well-designed clinical trials are necessary to identify factors that may trigger disease exacerbation after medication discontinuation in order to recognize the potential disadvantages of discontinuing treatment in patients who are previously successfully managed on TNF antagonists.

KW - Discontinuation

KW - Psoriasis

KW - Remission

KW - Tumor necrosis factor antagonist

KW - Withdrawal

UR - http://www.scopus.com/inward/record.url?scp=85072703591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072703591&partnerID=8YFLogxK

U2 - 10.5021/ad.2019.31.5.495

DO - 10.5021/ad.2019.31.5.495

M3 - Review article

AN - SCOPUS:85072703591

VL - 31

SP - 495

EP - 501

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 5

ER -